

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
HIGHLY SPECIALISED TECHNOLOGIES PROGRAMME

Equality impact assessment – Scoping

HST Afamelanotide for treating erythropoietic protoporphyria

Batch 47

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Consultees noted that children, young people and those aged over 70 years were excluded from the afamelanotide's marketing authorisation and considered that this represented a potential equality issue.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

This is not a potential equality issue that can be addressed by the Committee because NICE does not normally make recommendations outside the terms of the marketing authorisation of the technology being appraised, as published in the summary of product characteristics, unless instructed to do so by the Secretary of State.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

N/A

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes

to the matrix been made?
N/A

Approved by Associate Director (name):Sheela Upadhyaya ...

Date: 30 May 2017